Cencora sets July management change, shares under revised Barclays target
22.06.2026 - 17:47:17 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 17:43.
Cencora Inc. (US15135B1017) prepares for a change in its senior ranks while trading on the NYSE under the ticker COR. The pharmaceutical distributor has announced upcoming management moves and faces a lower price target from Barclays according to recent market coverage. MarketScreener company overview
What Reuters and filings show
On 15 June 2026, Cencora announced management changes effective 13 July 2026, according to a company news summary compiled by MarketScreener. Management changes item Earlier, on 28 May 2026, the company said Eva C. Boratto will become Chief Financial Officer and Executive Vice President effective 29 June 2026, while reaffirming its fiscal 2026 outlook in a separate communication. Finance chief and outlook note
The timing means Cencora will have its new CFO in place roughly two weeks before the wider management reshuffle in mid-July. The reaffirmed fiscal 2026 outlook suggests the board currently sees no need to adjust its earnings trajectory as it transitions finance leadership.
Analyst stance and NYSE trading context
On 10 June 2026, Barclays cut its price target on Cencora from 425 to 350 dollars but maintained an Overweight rating, as recorded in MarketScreener’s analyst action log. Analyst consensus and target data The adjustment narrows the implied upside but keeps the shares in a favored category for the UK bank.
Recent quote data from Stockscan shows Cencora shares at 271.83 dollars at the regular close, down 1.90 percent or 5.26 dollars on the day, with after-hours trading at 270.75 dollars. Stockscan COR overview At that level the shares trade clearly below the revised 350 dollar Barclays target while remaining within the S&P 500 health-care distribution peer group that includes AmerisourceBergen’s former peers such as McKesson and Cardinal Health.
All news and analysis on the Cencora shares
Key figures, ad-hoc releases and price data on the Cencora listing are bundled in the dedicated topic area.
How Cencora earns its money
Cencora generates most of its revenue by distributing branded and generic pharmaceuticals, specialty drugs and related health-care products to pharmacies, hospitals and clinics in the United States and internationally. The company also offers logistics and commercialization services for manufacturers, including specialty distribution and patient support programs.
Where the shares trade today
The Cencora shares (US15135B1017) most recently traded on the NYSE at 271.83 US dollars at the close, with after-hours indications at 270.75 dollars, based on data checked on 2026-06-22, 17:30.
Key data on the Cencora shares
- Company: Cencora Inc.
- ISIN: US15135B1017
- WKN: A3EVNY
- Ticker: COR
- Trading venue: NYSE
- Price (as of 2026-06-22, 17:30): 271.83 USD
- Market cap: 54.0 billion USD (as of 2026-06-22)
- Sector / industry: Health care distribution and services
- Index membership: S&P 500
- Next earnings date: 2026-08-01
Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical data and analyst assessments are not guarantees of future performance.
